In what form must ephedrine be administered?

Ephedrine is commonly used as a bronchodilator and decongestant, and its administration can vary based on the clinical context and formulations available. The combination of a solid oral dosage form of 400 mg guaifenesin with 25 mg of ephedrine is a recognized and acceptable formulation for certain therapeutic uses. The guaifenesin acts as an expectorant, aiding in the relief of coughs associated with colds or bronchitis, while the ephedrine provides the decongestant effect.

The specific dosage form highlighted reflects appropriate usage in a setting where both components can serve a combined therapeutic purpose. This form also aligns with regulations and practice standards that guide the prescription and dispensing of products containing both an expectorant and a decongestant agent in a combined oral solid dosage.

In contrast, other forms such as liquid only or sublingual tablets may not encapsulate the standard or common usage of ephedrine when combined with guaifenesin. Injectable ephedrine is typically reserved for more acute situations, such as anaphylactic reactions or severe asthma exacerbations, where immediate systemic effects are necessary, rather than the chronic management of symptoms for which the formulation in option C is typically prescribed